



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: McDONALD et al.

Serial No. 09/360,242

Filed: July 22, 1999

For: *METHODS AND COMPOSITIONS FOR  
TREATING SECONDARY TISSUE  
DAMAGE AND OTHER  
INFLAMMATORY CONDITIONS AND  
DISORDERS*

Art Unit: 1646

Examiner: Landsman, R.

**ELECTION, AMENDMENT AND RESPONSE TO NOTICE TO COMPLY WITH  
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE  
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Responsive to the Office Action, setting forth a Restriction Requirement and including a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed November 12, 1999, Applicant elects, with traverse, Group II, claims 25-39, drawn to methods of treatment of inflammatory disorders using the conjugates.

Although not set forth explicitly in the requirement, if an election of species of conjugate used in the methods is required, applicant elects the species in which the targeting agent is a chemokine and the targeted agent is a toxin. Pending claims 25-40 and 42-64 read on the elected species.

Please amend the above-captioned application as follows:

**IN THE SPECIFICATION:**

Please amend the specification as follows:

at page 3, line 1, replace "Baggiolini" with —Baggiolini—;

at page 6, line 21, insert —(SEQ ID NO. 93)— between " $\beta$ " and ",";

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on this date.

12/13/99

Date

*Kathy Holloway*  
Kathy Holloway